Pegylated recombinant human hyaluronidase (Halozyme)

N/A

Report date: 2024/01/02 20:03:52

Base Information

Drug NamePegylated recombinant human hyaluronidase (Halozyme)
Drug Alias Name聚乙二醇化重组人透明质酸酶 - HalozymePEGylated reombinant human hyaluronidasepegvorhyaluronidase alfaPEG-PH20PEG-rHuPH-20
ClassificationBiologics > Protein drugs > Enzyme > Recombinant enzymeBiologics > Protein drugs > Recombinant protein > Recombinant enzyme
Mechanisms of ActionHyaluronic acid modulators
TargetsHyaluronic acid
Therapy Area/IndicationsMetastatic breast cancerSolid tumoursHypercholesterolemia +[10] 
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryCzechiaBelgiumCanada +[24] 
CombinationsNo
Global Highest StatusPhase 2 Clinical
Highest Status in ChinaN/A
Originator CompaniesHalozyme Therapeutics Inc
China Registration ClassN/A

Develop Information

Active CompaniesHalozyme Therapeutics Inc
Inactive CompaniesYale UniversityThe University Of Texas MD Anderson Cancer CenterEisai Inc
Active IndicationsPancreatic NeoplasmsEsophageal Neoplasms
Inactive IndicationsMetastatic breast cancerSolid tumoursHypercholesterolemia +[8] 

Other Information

ATC CodeN/A
Related LinksN/A